Eaton’s Vehicle Group Partners With Ballard Fuel Cell Systems and National Renewable Energy Laboratory to Develop Heavy-Duty Truck Fuel Cell Technology
8.9.2021 13:30:00 EEST | Business Wire | Press release
Power management company Eaton today announced its Vehicle Group has partnered with leading fuel system manufacturer Ballard Fuel Cell Systems, and the Department of Energy’s National Renewable Energy Laboratory (NREL), to develop heavy-duty truck fuel cell technology. The partnership is the result of a grant Eaton’s Vehicle Group received from the U.S. Department of Energy to develop highly efficient hydrogen fuel cells capable of powering heavy-duty machinery.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210908005019/en/
Eaton’s TVS technology to provide precise airflow for hydrogen fuel cells. (Photo: Business Wire)
The new fuel cell technology will leverage Eaton’s Twin Vortices Series (TVS) technology to improve fuel efficiency. This marks another important step in Eaton’s commitment to decarbonizing the transportation sector, building on the company’s more than two decades of investments and solutions that help to mitigate climate change.
“Our TVS supercharger technology provides fuel cell manufacturers with a precise amount of controlled air to increase power and efficiency,” said Karl Sievertsen, vice president and chief technology officer, Eaton’s Vehicle Group. “The efficiency of competitive fuel cells is lower because most hydrogen fuel cells use simple fans for air flow, which produces less pressure and is not controllable.”
Eaton will leverage its Corporate Research Labs in Golden, Colorado and Additive Manufacturing Center of Excellence in Southfield, Michigan to produce the technology, using cutting-edge power electronics and advanced 3D-printing. Eaton’s Vehicle Group will design and test a subscale, proof-of-concept system prototype utilizing its TVS technology that delivers a significant reduction in air system power consumption and fuel cell efficiency for heavy-duty truck applications.
Eaton’s TVS technology is ideal for harsh environments, as it can tolerate water, has operating maps with broad efficiency, and provides accurate air flow control in proportion to speed. These properties enable a water applicator to replace the humidifier to achieve higher operating pressure ratios and isentropic efficiencies.
“The innovation will be demonstrated in a laboratory setting and will become a springboard for U.S. advanced manufacturing capabilities and technology leadership,” Sievertsen added.
Eaton is a global leader in supercharger technology, having produced more than 9 million units over more than 30 years. All Eaton supercharger components are produced in-house utilizing state-of-the-art manufacturing processes and feature a patented rotor coating for improved efficiency. Eaton’s powder coating fills gaps between rotor lobes, tips and faces to mitigate air leakage and creates a near-zero clearance between components, resulting in optimal performance.
“We’re honored to be partnering with Ballard and the NREL to build this new, innovative technology that will address global climate change,” said Sievertsen. “Eaton has a long history of working with our industry counterparts and federal research organizations to create sustainable solutions, reduce our footprint and advance our vision of improving the quality of life and the environment.”
Learn more about Eaton’s 2030 Sustainability Goals.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 85,000 employees. For more information, visit www.eaton.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210908005019/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom